|
pubmed:abstractText |
After a brief review of the qualities of the new triphasic contraceptive preparation Trisistone and some of its advantages in comparison with the other combined contraceptive drugs the authors report on the results from the first study, carried out in our country, on the therapeutic effect of Trisistone. Thirty-eight women with various gynecological diseases were treated. The largest group was that of women with irregular bleedings. In this group the effect was not good in all women. It was found that Trisistone had limited possibilities to control irregular uterine bleedings, which most probably was connected with its comparatively low dose of steroid hormones. The side effects were comparatively slight and not quite frequently. The most frequent side effect was the occurrence of irregular bleeding in 9.5% of the treated women. The state without any side effects was improved in 30.1% of the patients. Best results were found in women with postcastration syndrome, hypoestrogenism and congenital anomalies in the development of ovaries--primary ovarian dysgenesis. Trisistone is especially suitable for substituted treatment in women with ovarian hormonal deficit.
|
|
pubmed:otherAbstract |
PIP: The therapeutic efficacy of the new triphasic contraceptive agent trisistone was evaluated in 42 women (20-35 years old) with various gynecological diseases. The group included 25 with uterine hemorrhage, 4 with post-castration syndrome, 4 with endometriosis, 4 with hypogonadism, and 5 with other diseases. The drug was dispensed monthly. The patients received 1 to 14 packages of trisistone (average number 3-4). The first phase consisted of 6 violet tablets containing 0.003 mg of ethinyl estradiol and 0.05 mg of levonorgestrel; the second phase consisted 6 pink tablets containing 0.04mg of ethinyl estradiol and 0.075 mg of levonorgestrel and third phase consisted of 9 orange tablets containing 0.03 mg of ethinyl estradiol and 0.125 mg of levonorgestrel. Of 42 patients, 16 had stopped taking the drug after the first cycle, while 26 showed clinical improvement. The treatment was the most effective in patients with estrogen and gestagen insufficiency, luteal insufficiency, and primary ovarian dysgenesis. Side-effects of trisistone included hemorrhage (9.5%), headache (7.1%), sensation of pregnancy (7.1%), dizziness (2.4%), and nausea (2.4%).
|
